DKK456.15
3.98% yesterday
Copenhagen, May 20, 05:00 pm CET
ISIN
DK0062498333
Symbol
NOVO B
Sector
Industry

Novo Nordisk Target price 2025 - Analyst rating & recommendation

Novo Nordisk Classifications & Recommendation:

Buy
59%
Hold
31%
Sell
9%

Novo Nordisk Price Target

Target Price DKK655.26
Price DKK456.15
Potential
Number of Estimates 26
26 Analysts have issued a price target Novo Nordisk 2026 . The average Novo Nordisk target price is DKK655.26. This is higher than the current stock price. The highest price target is
DKK900.00 97.30%
register free of charge
, the lowest is
DKK350.00 23.27%
register free of charge
.
A rating was issued by 32 analysts: 19 Analysts recommend Novo Nordisk to buy, 10 to hold and 3 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Novo Nordisk stock has an average upside potential 2026 of . Most analysts recommend the Novo Nordisk stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Billion DKK 290.40 334.51
25.03% 15.19%
EBITDA Margin 50.95% 49.26%
6.23% 3.31%
Net Margin 34.61% 35.10%
2.80% 1.42%

25 Analysts have issued a sales forecast Novo Nordisk 2025 . The average Novo Nordisk sales estimate is

DKK335b
Unlock
. This is
10.35% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
DKK353b 16.46%
Unlock
, the lowest is
DKK318b 5.02%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 DKK290b 25.03%
2025
DKK335b 15.19%
Unlock
2026
DKK386b 15.32%
Unlock
2027
DKK429b 11.14%
Unlock
2028
DKK470b 9.51%
Unlock
2029
DKK524b 11.58%
Unlock

20 Analysts have issued an Novo Nordisk EBITDA forecast 2025. The average Novo Nordisk EBITDA estimate is

DKK165b
Unlock
. This is
5.08% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
DKK178b 13.35%
Unlock
, the lowest is
DKK131b 16.53%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 DKK148b 32.83%
2025
DKK165b 11.39%
Unlock
2026
DKK195b 18.60%
Unlock
2027
DKK221b 13.24%
Unlock
2028
DKK234b 5.85%
Unlock
2029
DKK279b 19.02%
Unlock

EBITDA Margin

2024 50.95% 6.23%
2025
49.26% 3.31%
Unlock
2026
50.66% 2.84%
Unlock
2027
51.62% 1.89%
Unlock
2028
49.89% 3.35%
Unlock
2029
53.21% 6.65%
Unlock

18 Novo Nordisk Analysts have issued a net profit forecast 2025. The average Novo Nordisk net profit estimate is

DKK117b
Unlock
. This is
12.79% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
DKK120b 15.61%
Unlock
, the lowest is
DKK115b 10.16%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 DKK100b 21.54%
2025
DKK117b 16.83%
Unlock
2026
DKK139b 18.76%
Unlock
2027
DKK159b 13.95%
Unlock
2028
DKK171b 7.38%
Unlock
2029
DKK200b 17.05%
Unlock

Net Margin

2024 34.61% 2.80%
2025
35.10% 1.42%
Unlock
2026
36.15% 2.99%
Unlock
2027
37.06% 2.52%
Unlock
2028
36.34% 1.94%
Unlock
2029
38.12% 4.90%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share DKK 22.63 26.44
21.54% 16.84%
P/E 16.59
EV/Sales 6.06

18 Analysts have issued a Novo Nordisk forecast for earnings per share. The average Novo Nordisk EPS is

DKK26.44
Unlock
. This is
12.80% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
DKK27.10 15.61%
Unlock
, the lowest is
DKK25.82 10.15%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 DKK22.63 21.54%
2025
DKK26.44 16.84%
Unlock
2026
DKK31.40 18.76%
Unlock
2027
DKK35.78 13.95%
Unlock
2028
DKK38.42 7.38%
Unlock
2029
DKK44.97 17.05%
Unlock

P/E ratio

Current 18.68 58.72%
2025
16.59 11.19%
Unlock
2026
13.97 15.79%
Unlock
2027
12.26 12.24%
Unlock
2028
11.42 6.85%
Unlock
2029
9.76 14.54%
Unlock

Based on analysts' sales estimates for 2025, the Novo Nordisk stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 6.68 59.24%
2025
6.06 9.35%
Unlock
2026
5.25 13.29%
Unlock
2027
4.72 10.03%
Unlock
2028
4.31 8.69%
Unlock
2029
3.87 10.38%
Unlock

P/S ratio

Current 6.43 60.62%
2025
5.82 9.38%
Unlock
2026
5.05 13.29%
Unlock
2027
4.54 10.03%
Unlock
2028
4.15 8.68%
Unlock
2029
3.72 10.38%
Unlock

Current Novo Nordisk Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
BERENBERG
Locked
Locked
Locked Apr 07 2025
REDBURN ATLANTIC
Locked
Locked
Locked Apr 06 2025
NYKREDIT MARKETS
Locked
Locked
Locked Apr 03 2025
JEFFERIES
Locked
Locked
Locked Apr 02 2025
HSBC
Locked
Locked
Locked Mar 23 2025
ODDO BHF
Locked
Locked
Locked Mar 13 2025
STIFEL EUROPE
Locked
Locked
Locked Mar 09 2025
Analyst Rating Date
Locked
BERENBERG:
Locked
Locked
Apr 07 2025
Locked
REDBURN ATLANTIC:
Locked
Locked
Apr 06 2025
Locked
NYKREDIT MARKETS:
Locked
Locked
Apr 03 2025
Locked
JEFFERIES:
Locked
Locked
Apr 02 2025
Locked
HSBC:
Locked
Locked
Mar 23 2025
Locked
ODDO BHF:
Locked
Locked
Mar 13 2025
Locked
STIFEL EUROPE:
Locked
Locked
Mar 09 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today